Tango Therapeutics generated a STK11-deleted MC38 mouse cancer model and, through an in vivo CRISPR screening platform, found that HDAC1 is a key target mediating immune evasion in STK11-deficient tumors. This evidence concerns the gene HDAC1 and cancer.